About us

James has extensive experience across commissioning, consultancy, and industry roles in market access. He began his career in commissioning at University Hospitals Birmingham before moving to Bridgehead International (acquired by GfK and subsequently IPSOS), where he delivered a wide range of access projects including pricing, reimbursement, payer engagement, health economic modelling, due diligence, advisory boards, clinical trial support, and payer research.

He then gained industry experience at Norgine, where he served as Global Market Access Lead for assets in hepatology and oncology, covering pre-launch to launch execution. His responsibilities included pricing strategy, reimbursement and HTA across Europe, HEOR strategy, payer engagement tools and rollout, life cycle management, and due diligence of new assets. He has led and supported multiple successful HTA submissions in Europe and contributed to broader commercial activities, including brand campaign development and global marketing materials.

“I am driven by striking a fair balance between demand and supply in healthcare systems”

Rachel holds a PhD in Cell Physiology and Pharmacology from the University of Leicester and a First-Class Undergraduate Masters degree in Molecular and Cellular Biology from the University of Bath.

Rachel has over a decade of experience in market access consultancy, working across pharmaceuticals, medical devices, drug-device combinations and digital health. Her therapy area expertise is varied and includes dermatology, rare diseases, oncology, HIV and NASH.

In a previous roles she has been responsible for providing strategic oversight to research projects to ensure overall objectives were met. She has extensive project experience that ranges from mapping and understanding the European market for medical devices and diagnostics, including TPP testing, product positioning, HTA and reimbursement landscapes, procurement routes and price potential.

“I am driven by the challenge of identifying and communicating the value of newly developed drugs and devices to ensure maximum access for those in need.”

“I’m passionate about helping companies unlock the full value of their healthcare assets and ensuring patients have access to life-changing innovations.”

“I am committed to helping patients, healthcare systems and pharma to identify sustainable solutions for healthcare innovation and access.”

Maddy is experienced in both qualitative and quantitative research across a wide range of therapy areas, including rare diseases, oncology and haematology. Previous work has involved supporting in the development of a European launch strategy for a new gene therapy, understanding the appropriate economic modelling technique for the long-term extrapolation of overall survival, and developing insights into the European requirements for a phase III clinical development programme.

Maddy has experience in project management, most recently demonstrated through the leadership of a pro bono programme advocating for action to improve health outcomes for sickle cell and young stroke patients.

Maddy completed her BSc Biomedical sciences degree at the University of Manchester, including an industrial placement year in the Central Nervous System Diseases department at Boehringer Ingelheim.

“I am excited to use innovative market research tools in order to help patients gain faster access to potentially life-changing drugs and health technologies”

Adam holds a First-Class Honours Degree in Biomedical Science from the University of Surrey, and an MSc in Science Communication from the University of Manchester. Adam has five years experience working in the market access strategy and value communication field, working with pharmaceutical and medical device companies throughout their products lifecycle, to optimise their commercial potential, value and market access strategy.

Adam has experience in leading and delivering an extensive range projects, from early disease landscaping, pricing opportunity assessments and launch strategy development, through to evidence generation, value tools, HTA submissions, and stakeholder insights. His experience spans across numerous global markets as well as disease areas, including rare diseases, oncology, neurology, respiratory, diabetes etc.

“Being part of a journey that helps to bring new and innovative medicines to patients, particularly those with a high unmet need, is what drives me in my career”

Nick’s educational background comprises of a BSC in Biology and a Biotechnology and Enterprise MSc, both awarded at the University of Manchester. During his bachelor’s, Nick gained lab experience while investigating the effects of the parasite Trichuris muris on intestinal myofibroblast activation using fluorescent microscopy. His Masters research focussed on a bioinformatic analysis of Single Nucleotide Polymorphisms within human YKL-40 gene and how these may contribute to disease conditions through alteration of the protein’s tertiary structure. This gave Nick an appreciation of the importance of both laboratory and desk-based research in uncovering scientific breakthroughs.

His Masters also had a heavy focus on the commercial aspects of the life sciences industry in the form of a business project with the aim of bringing a novel electronic biosensor to market. Everything from product design, clinical trial requirements, regulatory processes, market selection and product launch had to be reported on, culminating in a final business pitch. Nick found the process to be highly stimulating and this led him to pursue a career in market access.

“I am passionate about working at the forefront of scientific breakthroughs and am excited to see the impact I can have on the commercialisation of new medicines. I believe I will find it rewarding both intellectually but also morally, knowing that I was able to contribute to the medical access of some of the most neglected diseases.”

Tugce is a biologist by training, with seven years of experience in translational research from cardiology to ophthalmology. She graduated from Aston University with a PhD in tissue engineering, and a post-doctoral stint at King’s College London. ​

Tugce has three years of experience in strategic consulting, supporting global pharmaceutical clients across diverse therapeutic areas, ranging from rare diseases to oncology. ​Her work has focused on optimising payer and KOL communication materials, conducting primary and secondary research, and delivering pricing and market access insights to inform strategy. She has supported projects across US, EU5, Brazil, and Japan, building a deep understanding of access and reimbursement landscapes across key healthcare markets. ​​

“I am passionate about enabling faster patient access to innovation by turning data into strategy.”

Bhakti previously worked as a dentist in India and recently completed her MSc in Health Management from City, University of London with distinction. During her masters, she became proficient in conducting qualitative research, systematic and literature reviews. She did her dissertation on ‘Psychological challenges faced by children and adolescents having diabetes’ and worked on various projects on topics including- Striking balance between pharmaceutical innovation and affordability: the key challenges for COVID-19 vaccine in terms of Health Economics, Monoclonal-Antibodies, Telehealth, Checkpoint-Inhibitors. As a part of her masters, she also prepared a consultancy report for a client on the key aspects of the launch of a health technology in Midwest USA focusing on market landscape, entry strategies, pricing, competitor analysis and potential partnerships.

“Being from a medical background and having volunteered with several NGOs, my experiences highlighted the importance, as well as spawned my interest, in providing rapid patient access to newer technologies and drugs. I look forward to working with clients to ensure that ground-breaking innovations reach the people who need them on time.”

Orla completed her BSc in Natural Sciences at The University of Leeds, where she majored in Chemistry and Biochemistry. The research project she undertook during her studies allowed her to explore the use of organoids in the development of treatments for Glioblastomas.

Orla has previously worked for a pharmaceutical company which gave her a valuable insight into the drug discovery to market process, and the health inequalities we face today.

“I am enthusiastic about working towards gaining better access to potentially life changing drugs for patients; in an industry that is ever evolving and ensuring that our insightful strategies are beneficial for both clients, payers and patients.”

Ethan holds an MSc in MedTech Innovation & Entrepreneurship from King’s College London and a BSc in Infection and Immunity from University College London. His academic background uniquely positions him with a solid foundation in both scientific research and business. At UCL, he gained experience in clinical research, investigating the impact of immune responses in HIV-positive and negative individuals post-vaccination against SARS-CoV-2, and co-authored a scientific paper published in iScience Cell Press. Driven by his passion for understanding disease, innovative technologies, and helping people, Ethan co-founded a diabetes MedTech start-up during his MSc. The start-up focused on developing a novel medical device for Lipohypertrophy in Type-1 Diabetics. Here, he gained firsthand experience in the intricacies of running a business, leading market research, forging strategic partnerships, and understanding the importance of working with key stakeholders to understand their unmet needs. He also navigated regulatory processes and honed his public speaking skills through numerous pitches to demonstrate the commercial viability of the device.

“I thoroughly enjoyed the dynamic nature of start-up life and am dedicated to improving patients’ quality of life through innovative medicines and health technologies. I believe market access will allow me to bring a unique perspective from my experiences in clinical research and co-founding a startup to continue making a meaningful impact.”

Marietta earned a First-Class degree in Arts & Sciences from UCL, an interdisciplinary program blending social sciences and health-focused modules, and a First-Class MSc in Public Policy from LSE, where she honed skills in analysing and presenting qualitative and quantitative research findings.

Working for a healthcare public affairs consultancy in Brussels, Marietta contributed to driving health policy and regulatory reforms to improve patient outcomes and healthcare systems. Marietta also worked at the European Parliament supporting an MEP actively involved in shaping EU health policy.

Her experience in monitoring and reporting on health policy developments as a public affairs consultant, allows her to identify core issues with clarity. Having developed and presented multiple client-ready deliverables, Marietta is well-equipped to address a wide range of client needs with precision and reliability.

“Working in the healthcare sector is a privilege as it gives me the opportunity to help strengthen patient access to new treatments. I truly believe that health is our greatest wealth!”

Amina holds an MSc in Drug Discovery and Pharma Management from University College London, where her research focused on the regulatory environments around gene therapy innovation and the market access challenges faced by manufacturers of high-cost therapies for rare diseases. Prior to this, her passion for healthcare led her to pursue a BSc in Biomedical Sciences at King’s College London.

Her previous experience as a junior management consultant at a boutique firm equipped her with the ability to add strategic value to every engagement, ensuring a proactive and results-driven approach in all her interactions.

“True innovation is only valuable when patients have access to it. It is imperative to empower clients with the right knowledge and insights to ensure patients can benefit from their life-changing medicines worldwide.”

Murtaza holds a BSc(Hons) Biomedical Sciences from The University of Manchester. During his final year at The University of Manchester Murtaza was part of a Life Sciences Enterprise Project where he developed a solution to address the absence of a pancreatic cancer screening program in the UK and crafted a business plan.

Murtaza has previously worked as a Market Access Intern at a global pharmaceutical company where he gained experience in Health Economic and Outcomes Research, Pricing, Portfolio Strategy, and Market Access.

“I am deeply committed to raising standards of care, driven by the belief that every patient should be able to access the therapy they need.”

“Without an effective market access strategy, even the most advanced therapies cannot reach patients. It is imperative that clients are equipped with meaningful insights to transform scientific progress into global patient access.”

“I am motivated by using evidence and data to support better decisions and real-world impact.”

Charlotte has specialised in healthcare market research for over ten years. She has worked in both consultancy and academia across multiple therapeutic areas including infectious disease, chronic disease and acute illness. An experienced project manager, Charlotte has conceptualised and led a diverse portfolio of projects across a wide geographic landscape, working with a diverse range of stakeholders including key opinion leaders, clinicians, payers, market access leads, patients and carers. Charlotte has a strong background in public health and healthcare service delivery and design, with a particular focus on understanding the patient journey and experience, and identifying the optimal positioning of diagnostic tools and therapies in the patient pathway with the aim to improve patient care and outcomes. Charlotte has a PhD in Children’s Health from the University of Exeter. She is an experienced qualitative researcher, with a desire to improve patient pathways and ultimately patient outcomes.

“I am passionate about working closely with key stakeholders, particularly patients, to understand where new diagnostics or therapies can have the biggest impact on the patient pathway and outcomes. My goal is to produce evidence-based research that informs healthcare decision making with the patient at the centre of the process and solution.”

Stefania is an experienced payer and KOL recruitment professional, having spent over a decade in healthcare market access consulting.  She has extensive experience managing global payer and clinician panels for healthcare research and in developing, supporting, and implementing online, on-demand stakeholder insight technologies.  Stefania most recently worked at Market Access Transformation as a senior global payer relationship manager in New York (USA) and London (UK), and before that she was at GfK Market Access (now IPSOS) in London overseeing the payer liaison team.  Before moving into the healthcare industry, she worked in the qualitative research unit at NatCen, Britain’s largest independent social research organisation.  In Rome (Italy), Stefania worked at Consorzio GAIA S.p.A. as a project manager on international environmental cooperation projects in the Balkans and East Asia.

She earned a B.A. in International Business and a diploma in Accounting and has completed project management training.

“I am committed to connecting manufacturers with the correct payers and clinicians, producing robust research that enables patients access to leading therapies”

Camilla holds a BA (Hons) in Business Management and Leadership from Coventry University London. Her academic background provided a strong foundation in strategic operations, communication, and stakeholder engagement.

Camilla’s most recent experience in the education sector at WSET involved extensive stakeholder engagement, where she coordinated with global partners, managed complex project logistics, and ensured regulatory compliance and accurate reporting.

Prior to this, she worked at King Edward VII’s Hospital, where she collaborated closely with clinicians, consultants, and patients. In this role, she managed sensitive healthcare data, supported the use of electronic health record systems, and upheld the highest standards of confidentiality and accuracy within a regulated clinical environment.

“I am committed to supporting market research that drives healthcare innovation, enabling the development of new medical insights that improve patient outcomes globally.”

Michal is an experienced Finance Manager with a strong background in transactional finance and financial operations. She holds a BA degree in accounting and is committed to advancing her financial expertise for continuous professional growth. She brings a wealth of expertise in managing end-to-end financial processes, including accounts payable and receivable, month-end close, and the implementation of robust internal controls.

Throughout her career, Michal has led finance transformation initiatives that have significantly enhanced process efficiency, streamlined workflows, and fostered effective cross-functional collaboration.

“I am particularly passionate about working in the healthcare sector, where I can apply my financial acumen to support organisational goals. I believe finance is more than just numbers, it’s about creating clarity and driving meaningful impact to support and contribute to the goal of facilitating an improvement in patients’ lives.”

Charlotte is a communications professional with over 15 years pharma industry and healthcare communications experience.

Charlotte’s breadth of experience spans global marketing and communications, strategic planning, crisis management, government affairs, patient advocacy, and employee engagement.

“I am passionate about the power of great communication and am motivated by delivering impactful programmes that benefit the most important stakeholder of all, patients”

Crystal brings a diverse perspective on systems and processes, honed through her experience across AI, sustainability, creative industries, and the nonprofit sector. Her multifaceted background allows her to approach operational challenges with innovative solutions, ensuring operations run smoothly and effectively, ultimately driving both impact and supporting operational growth.

“I’m committed to supporting Lightning Health’s infrastructure, allowing the team to innovate boldly and grow confidently.”

As Chairman of Bridgehead International, a market access consultancy acquired by GfK and subsequently IPSOS, David has spent the last two decades championing an effective dialogue between industry and payers. He is concerned that innovations should find their right place in the diagnosis and treatment of patients and that benefits from research are fully realised.

“I am using my experience to establish, with my colleagues, an efficient platform for product pricing to ensure timely access for patients.”

As Founder and Director of Bridgehead International, an international pricing consultancy divested to GfK, Fiona helped clients to identify, assess and adopt innovative technologies. She uses her experience to support the development of new drugs and medical devices for the benefit of innovators, health systems and patients.

“I see a real need to improve the efficiency of collection and analysis of market access data, from rapid early insights to in-depth studies”

Stuart has over thirty years’ experience in the pharmaceutical industry. During this time, he has worked across sales, marketing, public affairs and market access. Stuart started his pharmaceutical career with Servier before moving to Astra and then joining Pfizer UK in 1997.

Stuart had a number of roles at Pfizer, starting in Sales Management before setting up the Market Access team, one of the first in the UK at the time. Stuart then moved to Pfizer’s Government Affairs team in Brussels, before joining Eli Lilly as Head of European Public Affairs. There he was responsible for a cross-functional team covering Government Affairs, Communications, Policy Development, Patient Advocacy and Corporate Responsibility.

Stuart then moved into rare disease, firstly with Synageva as VP, European Market Access & Government Affairs, where he took an ultra-orphan medicine from phase III results to being ready for pricing & reimbursement submission in all major markets in nine months. He then joined Akcea as Head of Global Market Access, Pricing and Reimbursement and established the function at global and country level, prior to the launch of an ultra-orphan medicine in mid-2019.

Stuart now works as an independent advisor, supporting biotech companies looking to commercialise medicines for rare diseases internationally. His work includes commercial strategy & sequencing, global market access capacity and competency development and market access due diligence. Most recently, Stuart spent three years as a senior advisor for the public affairs firm Rud Pedersen, where he helped establish their EU healthcare team.

Dr Frances Macdonald has a broad background in product development, market access and commercial leadership.

Dr Macdonald was a member of the Scottish Medicines Consortium (SMC), the Scottish HTA agency, for 7 years as the lead industry representative, sponsored by the Association of the British Pharmaceutical Industry (ABPI). She chaired the joint SMC/industry user group forum, ensuring industry input and collaboration on the evolution of SMC processes and methods.

Earlier in her career, Dr Macdonald spent 7 years leading European Global Health Economic and Outcomes Research groups in Syntex (UK) followed by Roche (Basel). Within Roche, her team provided strategic advice plus operational support on health economics and pricing throughout the company, from basic research through to the commercial affiliates.

Dr Macdonald has also worked in a range of roles in clinical development, including Project Management, Clinical Pharmacology, and European Regulatory Affairs and led a Global Lifecycle team within the Roche oncology franchise. Frances also established and led the UK and Irish commercial subsidiary of Actelion as UK Managing Director. Dr Macdonald holds a PhD in Physiology from Glasgow University.

Chris brings with him 25+ years practical and academic experience within the pharmaceutical industry, across both Marketing and R&D having been Director of Global Pricing and Market Access (Oncology) at Astra Zeneca, Director Health Economics, Pricing, Reimbursement and Access at Allergan, Commercial Planning Manager at Fisons, and Portfolio Planning Manager at Novartis in Switzerland.

For the past 10 years he worked in Consultancy (Bridgehead International, GfK, and Ipsos) and in 2023 founded TealeHealth Ltd, a consultancy providing expert Advisory, Access, and Analytic support on Advanced Personalised Therapies.

Chris brings significant experience of identifying and overcoming hurdles along the whole value chain – clinical development, manufacturing, distribution, regulatory assessment, health technology assessment, market access, pricing, marketing, and product uptake. He specialises in helping companies understand the value and sustainability of their differentiation relative to the competition and the evidence requirements to underpin this.

Chris has a mathematics and operational research background having studied at Newcastle and Loughborough universities, and at INSEAD Business School in France. He is an occasional lecturer on health economics and pharmaceutical pricing and reimbursement at Kings College London and University of California (San Diego), a member of ISPOR (International Society for Pharmacoeconomics and Outcomes Research) and PMSA (Pharmaceutical Management Science Association).

Dr Rosemarie (Rosie) Delaney is an accomplished Market Access and Pricing leader with over 25 years of experience across pharmaceuticals, biotech, vaccines and medical devices. She brings deep expertise in global market access strategy, pricing and reimbursement, international reference pricing (IRP), value development and health technology assessment (HTA), supporting companies navigating increasingly complex global pricing and policy environments.

Rosie offers a rare combination of senior in-house leadership experience within global pharmaceutical organisations, and independent consulting expertise, enabling her to advise clients with a strong understanding of both corporate decision-making and practical execution.

Her most senior leadership role was at Indivior UK, where she led European and Canadian Access and Pricing strategies for treatments in Opioid Use Disorder. She has also held senior Market Access roles at Bristol-Myers Squibb (Cardiovascular Europe) and Sanofi Pasteur MSD (Vaccines, UK), underpinned by a strong commercial background from her earlier career in marketing and leadership roles at Servier Laboratories Ltd and Pall Medical. This blend of commercial and access experience gives Rosie a broad perspective on value, pricing, and access strategy. She began her career in academia, as a Lecturer in Clinical Pharmacology giving her a strong scientific foundation and a rigorous, evidence-based approach to strategy development.

Alongside her industry career, Rosie has extensive consultancy experience, providing fractional and project-based support to pharmaceutical and biotech companies including Pfizer, Norgine and Eisai EMEA, across multiple therapeutic areas, including Oncology, Atrial Fibrillation, Iron Deficiency Anaemia & Asthma.

In recent consulting engagements, Rosie has supported biotech clients on projects in Oncology and Anti-microbial Resistance, with her most recent work focused on evaluating the ex-US implications of emerging Most Favoured Nation (MFN) pricing policies, including international reference pricing exposure and launch sequencing risk.

Through Delaney Pharmaceutical Consulting (DPC) Ltd, Rosie partners with organisations seeking experienced strategic support, helping teams define value, assess policy risk and make informed global access and pricing decisions.